Skip to main content
. 2013 Jan;15(1):23–38. doi: 10.1593/neo.121502

Figure 7.

Figure 7

Rosiglitazone increases adiponectin expression, modulates adiponectin signaling molecule, inhibits clonogenicity and migration and invasion of breast cancer cells. (A) Breast cancer cells (MCF7 and MDA-MB-231) were treated with various concentrations of rosiglitazone and subjected to clonogenicity assay. Colonies containing >50 normal-appearing cells were counted. Rosiglitazone inhibited clonogenic potential of breast cancer cells. (B) MDA-MB-231 cells were subjected to scratch migration assay in the presence of rosiglitazone treatments as indicated. Plates were photographed immediately after scratching, 20 and 44 hours after rosiglitazone treatment at the identical location of the initial image. Rosiglitazone inhibited migration of breast cancer cells. (C) MDA-MB-231 cells were cultured in Matrigel invasion chambers followed by rosiglitazone treatment as indicated. The number of cells that invaded through the matrigel was counted in five different regions. The slides were blinded to remove counting bias. *P < .005, compared with untreated controls. Rosiglitazone treatment significantly reduced matrigel invasion potential of breast cancer cells. Representative images of cells invaded through matrigel are shown. Breast cancer cells (MDA-MB-231 and MDA-MB-468) were treated with 50 µM rosiglitazone for various intervals of time as indicated. Untreated cells are denoted as 0. (D) Total RNA was isolated followed by RT-PCR to analyze the expression of adiponectin using specific primer sets. (E) Total protein was isolated and equal amounts of proteins were resolved by SDS-PAGE and subjected to immunoblot analysis using specific antibodies for adiponectin. The blots are representative of multiple independent experiments. Rosiglitazone treatment increases adiponectin expression in MDA-MB-231 and MDA-MB-468 breast cancer cells. (F) MCF7 and MDA-MB-231 cells were treated with rosiglitazone as in D. Total protein was isolated and equal amounts of proteins were resolved by SDS-PAGE and subjected to immunoblot analysis using specific antibodies for pAMPK and AMPK. Actin was used as control.